SCM
MNPR icon

Sterling Capital Management’s Monopar Therapeutics MNPR Stock Holding History

Sterling Capital Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.67K Buy
72
+43
+148% +$2.66K ﹤0.01% 2457
2026
Q1 		$1.59K Hold
29
– – ﹤0.01% 3032
2025
Q4 		$1.89K Buy
29
+20
+222% +$1.63K ﹤0.01% 3074
2025
Q3 		$735 Sell
9
-1
-10% -$45 ﹤0.01% 3122
2025
Q2 		$358 Buy
+10
New +$363 ﹤0.01% 3191

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Sterling Capital Management's MNPR Position: Q2 2026 in Review

Sterling Capital Management increased its Monopar Therapeutics (MNPR) stake by 148% in Q2 2026, buying an estimated $2.66K and bringing the position to 72 shares worth $6.67K. The position accounts for ﹤0.01% of the portfolio, ranked #2457.

Sterling Capital Management first reported a position in MNPR in Q2 2025 and has held it in 5 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Sterling Capital Management held 72 shares of Monopar Therapeutics worth $6.67K as of Q2 2026.
  • Sterling Capital Management bought 43 Monopar Therapeutics shares in Q2 2026, an estimated $2.66K.
  • Monopar Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2457 holding.
  • Sterling Capital Management first reported a position in Monopar Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.